Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells. In addition, the company is involved in research, develops, and collects data on all types of human cellular activities and medical laboratory tests. Further, the company sells dietary supplements, cosmetics, and dermo cosmetics. Medeze Group Public Company Limited was founded in 2010 and is based in Nakhon Pathom, Thailand.
Frequently asked questions
What sector does Medeze Group PCL (MEDEZE) operate in?
Medeze Group PCL belongs to the Other sector and operates in the Medical Care Facilities industry.
What is Medeze Group PCL (MEDEZE) current stock price?
As of the latest data, Medeze Group PCL stock price is THB 6.50, with a previous close of THB 6.50.
What is Medeze Group PCL (MEDEZE) current market capitalization?
Medeze Group PCL market cap is approximately 6.94 billion.
What is Medeze Group PCL (MEDEZE) Earnings Per Share (EPS)?
The trailing EPS is THB 0.14, and the forward EPS is THB 0.35.
What is Medeze Group PCL (MEDEZE) Price-to-Earnings (P/E) ratio?
Medeze Group PCL current P/E ratio is 46.43, with a forward P/E of 18.75.
Does Medeze Group PCL (MEDEZE) pay dividends?
Yes. Medeze Group PCL pays semiannual dividends with an annualized yield of 2.46% and an estimated annual payout of THB 0.16 per share.
When is the next ex-dividend date for Medeze Group PCL (MEDEZE)?
The next ex-dividend date is scheduled for October 29, 2026.
What is Medeze Group PCL (MEDEZE) beta (volatility) score?
Medeze Group PCL has a beta of 0.035, indicating lower volatility than the overall market.
